ALSUntangled #71: Nuedexta.

Autor: Sun Y; Neurology Department, University of Kentucky, Lexington, KY, USA., Benatar M; Department of Neurology, University of Miami, Miami, FL, USA., Mascías Cadavid J; Neurology Department, Hospital Carlos III-La Paz, Madrid, Spain., Ennist D; Origent Data Sciences Inc, Vienna, VA, USA., Wicks P; Wicks Digital Health, Lichfield, UK., Staats K; Staats Life Sciences Consulting, Los Angeles, CA, USA., Beauchamp M; Neuroscience Clinical Trials Unit, UNC Chapel Hill, NC, USA., Jhooty S; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Pattee G; Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA., Brown A; Department of Neurology, University of Miami, Miami, FL, USA., Bertorini T; Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA., Barkhaus P; Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA., Bromberg M; Department of Neurology, University of Utah, Salt Lake City, UT, USA., Carter G; St Luke's Rehabilitation Institute, Spokane, WA, USA, and., Bedlack R; Department of Neurology, Duke University, Durham, NC, USA., Li X; Department of Neurology, Duke University, Durham, NC, USA.
Jazyk: angličtina
Zdroj: Amyotrophic lateral sclerosis & frontotemporal degeneration [Amyotroph Lateral Scler Frontotemporal Degener] 2024 Feb; Vol. 25 (1-2), pp. 218-222. Date of Electronic Publication: 2023 Jul 26.
DOI: 10.1080/21678421.2023.2239292
Abstrakt: Nuedexta is a combination of dextromethorphan hydrobromide and quinidine sulfate and was approved by the Food and Drug Administration (FDA) in 2010 to treat pseudobulbar affect (PBA). There have since been anecdotal case reports of bulbar function improvements after Nuedexta treatment. Here, we review the off-label use of Nuedexta for improving bulbar function in people with ALS. Nuedexta has plausible mechanisms for protecting brain stem motor neurons via its effects on S1R and glutamate excitotoxicity. Recent clinical trials support that Nuedexta can improve bulbar function in PALS, with or without PBA. Nuedexta causes mild to moderate side effects. Based on this information, we support considering Nuedexta treatment for bulbar dysfunction in ALS patients with or without PBA.
Databáze: MEDLINE